Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CombinaiR3: First-line Strategy for Primary Extrapulmonary Ewing Tumours
NCT03011528Phase 2Completed
- Sponsor
- Institut Curie
- Start
- Dec 2016
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label trial of vincristine sulfate liposome injection, pegylated liposomal doxorubicin, cyclophosphamide, ifosfamide, etoposide and 5 more in Ewing sarcoma (4 arms), sponsored by Institut Curie. Primary endpoint: Event-Free Survival at 18 months. Started Dec 2016; status: completed.
02
Drugs
vincristine sulfate liposome injectionpegylated liposomal doxorubicincyclophosphamideifosfamideetoposide
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT03011528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03011528.